Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affects systemic
small vessels and is accompanied by the presence of ANCAs in the serum. This disease …

Despite being the second least represented granulocyte subpopulation in the circulating
blood, eosinophils are receiving a growing interest from the scientific community, due to their …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …

The provisional EULAR recommendations address several aspects of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by …

Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …

Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis.
However, glucocorticoids used as treatment contribute to the morbidity and mortality of …

Background: Biannual rituximab infusions over 18 months effectively maintain remission
after a “standard” remission induction regimen for patients with antineutrophil cytoplasmic …

Objective To compare individually tailored, based on trimestrial biological parameter
monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of …